You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 7,470,721

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,470,721

Title:	Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways
Abstract:	Methods are provided for the identification, biochemical characterization and therapeutic use of agents which impact PTEN, p53, PI-kinase and AKT mediated cellular signaling.
Inventor(s):	Durden; Donald L. (Indianapolis, IN)
Assignee:	Indiana University Research and Technology Corporation (Indianapolis, IN)
Application Number:	10/712,850
Patent Claims:	1. A method for the treatment of cancer in a patient in need thereof, comprising the administration of an effective amount of at least one PI-3kinase inhibitor selected from the group consisting of LY294002 and Wortmannin, wherein said PI-3 kinase inhibitor effectively inhibits aberrant tumor-associated angiogenesis, said method further comprising assessing inhibition of angiogenesis following administration of said PI-3 kinase inhibitor. 2. The method as claimed in claim 1, wherein said PI-3 kinase inhibitor effectively inhibits cancer cell metastasis. 3. The method as claimed in claim 1, further comprising the administration of at least one additional chemotherapeutic agent. 4. The method as claimed in claim 3, wherein said at least one additional chemotherapeutic agent is selected from the group consisting of alkylating agents, antimetabolites, asparaginase, vincristine, vinblastlne, anthracyclines, microtubule disrupting agents, taxol, herceptin, and etoposides. 5. The method as claimed in claim 1, wherein said PI-3 kinase inhibitor is LY294002. 6. The method of claim 1, wherein said cancer is chemoresistant and administration of said at least one PI-3 kinase inhibitor is effective to enhance the chemosensitivity of cells in said cancer. 7. The method as claimed in claim 6, further comprising the administration of at least one additional chemotherapeutic agent. 8. The method as claimed in claim 7, wherein said at least one additional chemotherapeutic agent is selected from the group consisting of alkylating agents, antimetabolites, asparaginase, vincristine, vinblastine, anthracyclines, microtubule disrupting agents, taxol, herceptin, and etoposides. 9. The method as claimed in claim 6, wherein said PI-3 kinase inhibitor is LY294002. 10. A method for the treatment of cancer in a patient in need thereof, comprising the administration of an effective amount of at least one PI-3kinase inhibitor selected from the group consisting of LY294002 and Wortmannin, wherein said PI-3 kinase inhibitor effectively inhibits aberrant tumor-associated angiogenesis, wherein said cancer is radioresistant and administration of said at least one PI-3 kinase inhibitor is effective to enhance the radiosensitivity of cells in said cancer, said method futher comprising assessing inhibition of angiogenesis following administration of said PI-3 kinase inhibitor. 11. The method as claimed in claim 10, further comprising the administration of at least one additional chemotherapeutic agent. 12. The method as claimed in claim 11, wherein said at least one additional chemotherapeutic agent is selected from the group consisting of alkylating agents, antimetabolites, asparaginase, vincristine, vinblastine, anthracyclines, microtubule disrupting agents, taxol, herceptin, and etoposides. 13. The method as claimed in claim 10, wherein said PI-3 kinase inhibitor is LY294002. 14. The method as claimed in claim 1 comprising the targeted administration of said PI-3kinase inhibitor to cancer tissues to induce stress induced apoptosis thereof and inhibit tumor-associated angiogenesis. 15. The method as claimed in claim 14, wherein said apoptosis is p53 mediated. 16. The method as claimed in claim 14, wherein said agonist is the PI-3 kinase inhibitor LY294002.

Details for Patent 7,470,721

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978	⤷ Try a Trial	2020-05-30
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998	⤷ Try a Trial	2020-05-30
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017	⤷ Try a Trial	2020-05-30
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.